SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM). The Company announced its first prototype in June 2023. The KnowU is the result of an accelerated development process over the last eight months..

西雅图--（商业新闻短讯）--Know Labs，Inc.（纽约证券交易所美国代码：KNW），一家新兴的非侵入性医疗诊断技术开发商，今天宣布了KnowU™，它的可穿戴式非侵入性连续血糖监测仪（CGM）。该公司于2023年6月宣布了其第一个原型。KnowU是过去八个月加速开发过程的结果。。

The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company’s prototype to validate stability outside of the lab, and is now miniaturized and wearable..

KnowU集成了该公司计划提交FDA批准的传感器。这种专有传感器已在实验室环境中经过测试并证明稳定准确。它被包括在公司的原型中，以验证实验室外的稳定性，现在已经小型化和可穿戴。。

The KnowU can be worn with an adhesive, allowing the user to clip the sensor on and off, or on the wrist or forearm with a strap. The device, which is significantly smaller and lighter than the prototype, includes on-board computing power and built-in machine learning capabilities. The KnowU is designed to optimize the customer experience – expected to last for years, eliminate costly disposables, have a rechargeable battery, and connect with an easy-to-use companion mobile app.

KnowU可以与粘合剂一起佩戴，使用户可以用带子将传感器夹在手腕或前臂上。该设备比原型小得多，重量也轻得多，包括车载计算能力和内置的机器学习功能。KnowU旨在优化客户体验，预计可使用多年，省去昂贵的一次性用品，配备可充电电池，并与易于使用的配套移动应用程序连接。

Click here to watch a video for more insight into specific KnowU features..

单击此处观看视频，以更深入地了解KnowU的特定功能。。

The KnowU brings Know Labs closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace. As the Company prepares for FDA clinical trials, the KnowU device will support accelerated data collection, including determining the technology’s performance throughout continuous wear, on different locations on the body, and within more expansive glycemic ranges and diverse populations..

KnowU使KnowLabs更接近向全球市场提供世界上第一台无创血糖监测仪。随着该公司为FDA临床试验做准备，KnowU设备将支持加速数据收集，包括确定该技术在持续佩戴过程中，在身体不同部位，以及在更广泛的血糖范围和不同人群中的性能。。

“The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes,” said Ron Erickson, CEO and Chairman at Know Labs. “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes.

Know Labs首席执行官兼主席罗恩·埃里克森（RonErickson）表示：“全球糖尿病患病率正在以惊人的速度增长。数百万人在获得有效管理糖尿病所需的技术和治疗方面面临重大障碍。”。“Know Labs致力于提供一种可获得、价格合理且准确的解决方案，以改善当前的护理标准，提高糖尿病患者的生活质量。

The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”.

KnowU使我们更接近一个未来，糖尿病管理中的公平护理将成为现实。”。

The KnowU is built upon the solid scientific foundation underlying Know Labs’ technology. Its proprietary radiofrequency (RF) sensor measures glucose levels using dielectric spectroscopy by rapidly scanning a large range of RF frequencies. It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels.

KnowU建立在KnowLabs技术的坚实科学基础之上。其专有的射频（RF）传感器通过快速扫描大范围的射频频率，使用介电光谱法测量葡萄糖水平。它记录在每个频率检测到的电压值，用商业秘密机器学习算法对实时连续血糖水平进行量化。

The KnowU exploits the dielectric properties of glucose, a polar molecule in the body, including its ability to store electrical energy in an electrical field (known as permittivity) as measured through a voltage reading received after broadcasting each frequency. As the leading worldwide IP holder in non-invasive blood glucose monitoring with more than 270 patents issued, pending and in process, Know Labs has created a defensible moat surrounding its technology.

KnowU利用葡萄糖（一种体内极性分子）的介电特性，包括它在电场（称为介电常数）中存储电能的能力，该电场是通过广播每个频率后接收到的电压读数来测量的。作为无创血糖监测领域全球领先的知识产权持有者，Know Labs已发布、正在申请和处理270多项专利，围绕其技术建立了一条防御工事。

For more information, visit https://www.knowlabs.co/technology..

有关更多信息，请访问https://www.knowlabs.co/technology..

During 2024, Know Labs will deploy the KnowU in large-scale, external clinical trials while making refinements to the device and its algorithms. To learn more about the development process for the KnowU, visit https://www.knowlabs.co.

2024年期间，Know Labs将在大规模的外部临床试验中部署KnowU，同时对设备及其算法进行改进。要了解KnowU开发过程的更多信息，请访问https://www.knowlabs.co.

About Know Labs, Inc.

关于Know Labs，Inc。

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors.

Know Labs，Inc.是一家上市公司，其股票在纽约证券交易所（NYSE American Exchange）以股票代码“KNW”进行交易。该公司的平台技术使用光谱学将电磁能引导穿过物质或材料以捕获独特的分子特征。该技术可以集成到各种可穿戴、移动或台式形状因素中。

This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor.

这种专利和正在申请专利的技术可以有效识别和监测以前只能通过侵入性和/或昂贵且耗时的实验室测试进行的分析物。该技术的第一个应用将是作为无创血糖监测仪销售的产品。

The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market..

该设备将为用户提供可访问且价格合理的血糖水平实时信息。该产品在上市前需要美国食品和药物管理局的批准。。

Safe Harbor Statement

安全港声明

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products.

本新闻稿包含的声明构成1995年《私人证券诉讼改革法案》、经修订的1933年《证券法》第27A节和经修订的1934年《证券交易法》第21E节所指的前瞻性声明。这些声明出现在本新闻稿的多个地方，包括所有不是关于Know Labs，Inc.，其董事或高管在以下方面的意图，信念或当前期望的历史事实声明：（i）融资计划；（ii）影响其财务状况或经营成果的趋势；（三）增长战略和经营战略；（iv）产品性能。

You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements.

您可以使用“可能”、“将”、“可能”、“应该”、“将”、“计划”、“预期”、“预期”、“继续”、“估计”、“项目”、“打算”、“可能”、“预测”、“可能”、“可能”、“潜在”等词语来识别这些陈述，其类似表达和变体旨在识别前瞻性陈述。

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

投资者需要注意的是，任何此类前瞻性陈述都不能保证未来的表现，并且涉及风险和不确定性，其中许多风险和不确定性超出了Know Labs，Inc.的控制能力，由于各种因素，实际结果可能与前瞻性陈述中预测的结果存在重大差异。

These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time.

这些风险和不确定性还包括公司向美国证券交易委员会提交的文件中讨论的其他风险因素，包括截至2023年9月30日的10-K表年度报告、10-Q表和8-K表，以及我们不时向美国证券交易委员会提交的其他文件。

These documents are available on the SEC Filings sec.

这些文件可在美国证券交易委员会档案管理委员会获得。